Abstract
Gene therapy for malignant glioma with the herpes simplex virus thymidine kinase/ganciclovir ( HSV-tk /GCV) system is already in the stage of clinical trials, but still needs major improvement to achieve greater clinical efficacy. The aim of this study was to determine whether combining HSV-tk /GCV gene therapy with temozolomide (TMZ), an alkylating drug clinically proven to be efficient in recurrent high-grade gliomas, would result in enhanced antitumor effect in malignant glioma in culture and in vivo. Human U87MG glioblastoma (GBM) cells with or without expression of HSV-tk were treated with different concentrations of GCV, TMZ, or both drugs. Cell viability was accessed by an automated microplate assay (MTT). The isobologram method and the combination index (CI) method of Chou-Talalay were used to measure the interactions between the two drugs when applied simultaneously. U87- tk and control U87 cells (5×106 each) were implanted in the flanks of nude mice, and animals were treated with GCV or TMZ or with both drugs. All tumors were measured and weighed at specified time points. IC50 for GCV was 511 μM in control U87 cells and 14.3 μM in U87- tk cells, resulting in 35.7-fold increase of toxicity in the HSV-tk –expressing cells. TMZ had an IC50 of 20.2 mM in control cells and 2.35 mM in U87- tk cells, resulting in 8.6-fold increase in sensitivity of the HSV-tk –expressing cells. TMZ and HSV-tk /GCV actions were synergistic (CI<1) in both control and U87- tk cells with higher synergism in U87- tk cells at high effect levels. Tumors expressing HSV-tk and treated with TMZ and GCV were significantly smaller than those treated by TMZ, but not by GCV. There was also a significant difference between the weight of HSV-tk expressing versus control tumors treated with TMZ, with GCV, or with both drugs. These data demonstrate synergism between HSV-tk /GCV and TMZ and higher sensitivity against TMZ in HSV-tk –expressing GBM cells. The potential importance for clinical studies combining both local tumor gene therapy and systemic chemotherapy should be explored further. Cancer Gene Therapy (2001) 8, 662–668.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Shugg D, Allen BJ, Blizzard L, et al . Brain cancer incidence, mortality and case survival: Observations from two Australian cancer registries Int J Cancer 1994 59: 765–770
Burger PC, Green SB . Patient age, histologic features and length of survival in patients with glioblastoma multiforme Cancer 1987 59: 1617–1625
Fine HA . The basis fort current treatment recommendations for malignant gliomas J Neurooncol 1994 20: 111–120
Kleihues P, Burger PC, Scheithauer BW . Histological Typing of Tumors of the Central Nervous System 2nd ed Berlin: Springer 1993
Prados MD, Levin V . Biology and treatment of malignant glioma Semin Oncol 2000 27: 1–10
Culver KW, Ram Z, Wallbridge S, et al . In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors Science 1992 256: 1550–1552
Moolten FL . Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy Cancer Res 1986 46: 5276–5281
Oldfield EH, Ram Z, Culver KW, et al . Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir Hum Gene Ther 1993 4: 39–69
Ram Z, Culver KW, Oshiro EM, et al . Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells Nat Med 1997 3: 1354–1361
Shand N, Weber F, Mariani L, et al . A phase 1–2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir Hum Gene Ther 1999 10: 2325–2335
Freeman SM, Abboud CN, Whartenby KA, et al . The “bystander effect”: tumour regression when a fraction of the tumour mass is genetically modified Cancer Res 1993 53: 5274–5283
Rainov NG . A Phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy for previously untreated glioblastoma multiforme in adults Hum Gene Ther 2000 11: 2389–2401
Baer JC, Freeman AA, Newlands ES, et al . Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells Br J Cancer 1993 67: 1299–1302
Bower M, Newlands ES, Bleehen NM, et al . Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma Cancer Chemother Pharmacol 1997 40: 484–488
Avgeropoulos NG, Batchelor TT . New treatment strategies for malignant gliomas Oncologist 1999 4: 209–224
Friedman HS, McLendon RE, Kerby T, et al . DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma J Clin Oncol 1998 16: 3851–3857
Newlands ES, O'Reilly SM, Glaser MG, et al . The Charing Cross Hospital experience with temozolomide in patients with gliomas Eur J Cancer 1996 32A: 2236–2241
Yang LY, Li L, Keating MJ, et al . Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin–DNA cross-link repair Mol Pharmacol 1995 47: 1072–1079
Ezzeddine ZD, Martuza RL, Platika D, et al . Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene New Biol 1991 13: 608–614
Chou TC, Talalay P . Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors Eur J Biochem 1981 115: 207–216
Chou TC, Talalay P . Quantitative analysis of dose–effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 1984 22: 27–55
Chou TC . The median-effect principle and the combination index for quantitation of synergism and antagonism In: Chou TC, Rideout DC, eds. Synergism and Antagonism in Chemotherapy New York: Academic Press 1991 61–102
Chou TC . Drug combinations: from laboratory to practice J Lab Clin Med 1998 132: 6–8
Chou TC, Motzer RJ, Tong Y, et al . Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design J Natl Cancer Inst 1994 86: 1517–1524
Chou TC, Hayball M . CalcuSyn for Windows, multiple drug dose–effect analyzer and manual Biosoft, Cambridge Place, Cambridge, UK 1996
Chen MS, Walker J, Prusoff WH . Kinetic studies of herpes simplex virus type 1-encoded thymidine and thymidylate kinase, a multifunctional enzyme J Biol Chem 1979 254: 10747–10753
Aghi M, Kramm CM, Chou TC, et al . Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies J Natl Cancer Inst 1998 90: 370–380
Faulds D, Heel RC . Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections Drugs 1990 39: 597
Arrowsmith J, Missailidis S, Stevens MF, et al . Antitumour imidazotetrazines: Part 37. Conjugation of the DNA major-groove alkylating imidazotetrazine mitozolomide to peptide motifs recognizing the minor groove Anticancer Drug Des 1999 14: 205–217
Alvino E, Pepponi R, Pagani E, et al . O(6)-benzylguanine enhances the in vitro immunotoxic activity of temozolomide on natural or antigen-dependent immunity J Pharmacol Exp Ther 1999 291: 1292–1300
Belanich M, Randall T, Pastor MA, et al . Intracellular Localization and intercellular heterogeneity of the human DNA repair protein O(6)-methylguanine–DNA methyltransferase Cancer Chemother Pharmacol 1996 37: 547–555
Aghi M, Chou TC, Suling K, et al . Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies Cancer Res 1999 59: 3861–3865
Ilsley DD, Lee S, Miller WH, et al . Acyclic guanosine analogs inhibit DNA polymerases alpha, delta, and epsilon with very different potencies and have unique mechanisms of action Biochemistry 1995 34: 2504–2510
Hammond LA, Eckardt JR, Baker SD, et al . Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies J Clin Oncol 1999 17: 2604–2613
Acknowledgements
This study was supported in part by Grants 2794A/0087H and 3067A/0029G from the Federal State of Saxony-Anhalt (NGR), BioRegio Grant 0311661/1402 from the Federal Ministry of Education and Research of Germany (N.G.R., C.M.K.), a grant from the E.-Kröner-Fresenius foundation (N.G.R.), and a grant from the Bartling Foundation Hannover (N.G.R.).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rainov, N., Fels, C., Dröege, J. et al. Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma. Cancer Gene Ther 8, 662–668 (2001). https://doi.org/10.1038/sj.cgt.7700355
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700355
Keywords
This article is cited by
-
Advances in local therapy for glioblastoma — taking the fight to the tumour
Nature Reviews Neurology (2022)
-
Gene therapy for human glioblastoma using neurotropic JC virus-like particles as a gene delivery vector
Scientific Reports (2018)
-
An armed, YB-1-dependent oncolytic adenovirus as a candidate for a combinatorial anti-glioma approach of virotherapy, suicide gene therapy and chemotherapeutic treatment
Cancer Gene Therapy (2015)
-
Thymidine Kinase Gene Delivery Using Curcumin Loaded Peptide Micelles as a Combination Therapy for Glioblastoma
Pharmaceutical Research (2015)
-
Improved therapeutic effect on malignant glioma with adenoviral suicide gene therapy combined with temozolomide
Gene Therapy (2013)